Spotlight on Mexico: Healthcare under AMLO – One year on
Andrés Manuel López Obrador (commonly referred to by his initials AMLO) was elected President of Mexico in a landslide victory of December 2018. As we near the end of the first year of his six year term, we caught up with local expert Dr Xavier Tello, CEO of Strategic Consulting, to make sense of the latest changes in the healthcare system and consider what they mean for pharmaceutical manufacturers wishing to enter the Mexican market.“It has been a wild ride under AMLO”, Dr Tello told us. The changes have been rapid, complicated and unpredictable, and here we attempt to deconstruct the major events of the last 12 months.
New hopes for Mexico
What will be the future of healthcare under the country's new administration?
In December 2018 the new Mexican President, Andres Manuel Lopez Obrador came into office after a landslide victory of over 65% of the votes (more than 30 billion voters). López Obrador was a former Mexico City mayor and has been a major political figure for over twenty years. Widely regarded as both a populist and nationalist, his ideology is to end poverty and improve the lives of his people by fighting corruption and increasing austerity within the government.
Deep Dive - MINT: opportunities in ‘frontier’ markets?
Published in Pharmaphorum’s Deep Dive magazine October 2017
According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are the countries he believes are poised for strong economic growth, like the emerging markets of BRIC (Brazil, Russia, India and China) before them. What are the prospects for pharma in MINT? Research Partnership’s Rachel Howard and Sue Rees investigate the pros and cons.
Interactive infographic: LATAM
An overview of the six most-commonly researched, largest pharma markets in Latin America
The LATAM region's largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With pharmaceutical sales of more than $64bn, it is an attractive market for pharma, however it is also one in which each market differs in terms of opportunities and challenges.
Exploring MINT: Part 1 - Mexico
Published in eyeforpharma 7 July 2014 by Rachel Howard
Buzz about Brazil (the ‘B’ in the ‘BRIC’ wave of emerging markets) has typically overshadowed the potential of Mexico, the second-largest pharmaceutical market in Latin America. However, recent years have seen significant changes to the Mexican healthcare system and regulations, which have led to pharma finally starting to sit up and take notice of the potential Mexico has to offer.